Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatment
Abstract
Abstract Potentially fatal non-immune effector cell–associated neurotoxicity syndrome neurotoxicities (NINTs) after B-cell maturation antigen–targeted chimeric antigen receptor (CAR) T-cell therapy have been linked to high CAR T-cell expansion. Cyclophosphamide to ablate CAR T cells is an effective strategy to mitigate steroid-refractory NINTs.
Article Details
Authors (15)
Viktoria Blumenberg
1Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
Benjamin R. Puliafito
1Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
Charlotte E. Graham
4Comprehensive Cancer Centre, King’s College London, London, United Kingdom
Mark B. Leick
Md. Raihan Chowdhury
1Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
Maxx King
1Massachusetts General Hospital, Boston, United States
Deshea L. Harris
1Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
Noopur S. Raje
1Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
Andrew R. Branagan
Department of Medicine, Massachusetts General Hospital, Boston
Andrew J. Yee
Department of Medicine, Harvard Medical School, Boston
Diana Cirstea
3Hematology and Oncology Division, Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
Kathleen M. E. Gallagher
1Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
Jorg Dietrich
3Division of Neuro-Oncology, Department of Neurology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
Marcela V. Maus
Matthew J. Frigault
3Massachusetts General Hospital, Boston, MA